Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Buy
51
AZN Quote, Financials, Valuation and Earnings
Last price:
$66.26
Seasonality move
:
1.27%
Day range:
$65.77 - $66.41
52-week range:
$60.47 - $87.68
Dividend yield:
2.24%
P/E ratio:
31.78x
P/S ratio:
4.04x
P/B ratio:
5.05x
Volume:
4.6M
Avg. volume:
6M
1-year change:
-1.62%
Market cap:
$205.4B
Revenue:
$45.8B
EPS (TTM):
$2.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.1B | $1.03 | 17.56% | 255.34% | -- |
|
AMGN
Amgen
|
$8.5B | $5.11 | 8.07% | 254.55% | $322.43 |
|
GSK
GSK PLC
|
$10.4B | $1.16 | -1.61% | 107.8% | $42.93 |
|
LLY
Eli Lilly and
|
$12.1B | $1.47 | 49.68% | 124.93% | $984.05 |
|
MRNA
Moderna
|
$1.2B | -$1.94 | -63.53% | -79.68% | $127.09 |
|
SNY
Sanofi SA
|
$13.7B | $1.38 | -9.77% | 26.36% | $63.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$66.26 | -- | $205.4B | 31.78x | $0.50 | 2.24% | 4.04x |
|
AMGN
Amgen
|
$262.65 | $322.43 | $141.2B | 33.63x | $2.25 | 3.43% | 4.35x |
|
GSK
GSK PLC
|
$34.08 | $42.93 | $69.5B | 22.16x | $0.39 | 4.59% | 1.77x |
|
LLY
Eli Lilly and
|
$783.17 | $984.05 | $743.5B | 84.67x | $1.30 | 0.66% | 17.33x |
|
MRNA
Moderna
|
$40.13 | $127.09 | $15.4B | -- | $0.00 | 0% | 3.07x |
|
SNY
Sanofi SA
|
$48.73 | $63.06 | $122.2B | 24.69x | $2.04 | 8.08% | 2.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.54% | -0.572 | 12.47% | 0.71x |
|
AMGN
Amgen
|
88.92% | -0.086 | 34.87% | 0.80x |
|
GSK
GSK PLC
|
53.41% | 0.747 | 26% | 0.52x |
|
LLY
Eli Lilly and
|
68.61% | 0.948 | 3.9% | 0.63x |
|
MRNA
Moderna
|
-- | 0.826 | -- | 3.95x |
|
SNY
Sanofi SA
|
23.02% | -0.094 | -- | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$10.5B | $2.1B | 9.41% | 16.72% | 16.85% | $2B |
|
AMGN
Amgen
|
$5.2B | $2B | 6.14% | 65.35% | 45.6% | $3.3B |
|
GSK
GSK PLC
|
$7.3B | $245.9M | 8.08% | 18.89% | 2.75% | $1.7B |
|
LLY
Eli Lilly and
|
$9.3B | $4.4B | 21.5% | 66.4% | 15.57% | -$458.9M |
|
MRNA
Moderna
|
$1.3B | -$70M | -17.44% | -17.44% | 1.46% | -$1.7B |
|
SNY
Sanofi SA
|
$11.1B | $4.5B | 4.56% | 5.8% | 26.62% | -$498.5M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 33.28%. AstraZeneca PLC's return on equity of 16.72% beat Amgen's return on equity of 65.35%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B AMGNAmgen61.07% $5.22 $67.9B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.83%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.76%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 AMGNAmgen10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Amgen offers a yield of 3.43% to investors and pays a quarterly dividend of $2.25 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.5B. AstraZeneca PLC's net income of $1.4B is lower than Amgen's net income of $2.8B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.78x while Amgen's PE ratio is 33.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.04x versus 4.35x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.04x 31.78x $13.6B $1.4B AMGNAmgen4.35x 33.63x $8.5B $2.8B
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -0.72%. AstraZeneca PLC's return on equity of 16.72% beat GSK PLC's return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B GSKGSK PLC70.08% -$0.04 $39.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.83%. On the other hand GSK PLC has an analysts' consensus of $42.93 which suggests that it could grow by 32.26%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 GSKGSK PLC2 4 0 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.349%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. GSK PLC offers a yield of 4.59% to investors and pays a quarterly dividend of $0.39 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.4B is higher than GSK PLC's net income of -$75.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.78x while GSK PLC's PE ratio is 22.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.04x versus 1.77x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.04x 31.78x $13.6B $1.4B GSKGSK PLC1.77x 22.16x $10.4B -$75.5M
-
Which has Higher Returns AZN or LLY?
Eli Lilly and has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 8.48%. AstraZeneca PLC's return on equity of 16.72% beat Eli Lilly and's return on equity of 66.4%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B LLYEli Lilly and81.02% $1.07 $45.4B -
What do Analysts Say About AZN or LLY?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.83%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that AstraZeneca PLC has higher upside potential than Eli Lilly and, analysts believe AstraZeneca PLC is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 LLYEli Lilly and15 6 0 -
Is AZN or LLY More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.
-
Which is a Better Dividend Stock AZN or LLY?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or LLY?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Eli Lilly and quarterly revenues of $11.4B. AstraZeneca PLC's net income of $1.4B is higher than Eli Lilly and's net income of $970.3M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.78x while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.04x versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.04x 31.78x $13.6B $1.4B LLYEli Lilly and17.33x 84.67x $11.4B $970.3M
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 0.7%. AstraZeneca PLC's return on equity of 16.72% beat Moderna's return on equity of -17.44%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B MRNAModerna72.29% $0.03 $11.9B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.83%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.87%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 MRNAModerna7 12 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $1.9B. AstraZeneca PLC's net income of $1.4B is higher than Moderna's net income of $13M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.78x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.04x versus 3.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.04x 31.78x $13.6B $1.4B MRNAModerna3.07x -- $1.9B $13M
-
Which has Higher Returns AZN or SNY?
Sanofi SA has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 19.88%. AstraZeneca PLC's return on equity of 16.72% beat Sanofi SA's return on equity of 5.8%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B SNYSanofi SA71.15% $1.24 $101.5B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.83%. On the other hand Sanofi SA has an analysts' consensus of $63.06 which suggests that it could grow by 29.41%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 SNYSanofi SA5 1 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.492%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.24%. Sanofi SA offers a yield of 8.08% to investors and pays a quarterly dividend of $2.04 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Sanofi SA pays out 82.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $13.6B, which are smaller than Sanofi SA quarterly revenues of $15.6B. AstraZeneca PLC's net income of $1.4B is lower than Sanofi SA's net income of $3.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.78x while Sanofi SA's PE ratio is 24.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.04x versus 2.30x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.04x 31.78x $13.6B $1.4B SNYSanofi SA2.30x 24.69x $15.6B $3.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
